A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease.

Amandeep SalhotraKaramjeet SandhuJames O'HearnHaris AliRyotaro NakamuraBadri G Modi

Published in: Expert review of clinical immunology (2022)

Belumosudil is approved for treatment of adult and pediatric patients ≥ 12 years with cGVHD after failing two lines of therapy based on results of the ROCKstar study that showed high overall response rates (ORR), favorable adverse effect profiles, and low rates of severe infections. With the availability of three new agents for treatment of cGVHD, treating physicians have more therapeutic options for patients and have additional options of development new clinical trials using a combination of recently approved drugs.

Keyphrases

clinical trial
end stage renal disease
primary care
newly diagnosed
ejection fraction
chronic kidney disease
early onset
stem cells
combination therapy
emergency department
prognostic factors
mesenchymal stem cells
drug induced
electronic health record